Treatment of migraine with monoclonal antibodies
- 13 May 2022
- journal article
- other
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 22 (6) , 707-716
Abstract
: In the few last years, a new family of drugs, anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs), has been developed for migraine therapy. Anti-CGRP mAbs are highly effectiv...Keywords
This publication has 65 references indexed in Scilit:
- Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study ( IBMS‐II )Headache: The Journal of Head and Face Pain, 2013
- Endothelial progenitor cellsNeurology, 2012
- Adherence with Migraine Prophylaxis in Clinical PracticePain Practice, 2012
- GRADE guidelines: 9. Rating up the quality of evidenceJournal of Clinical Epidemiology, 2011
- Tolerance and Loss of Beneficial Effect During Migraine Prophylaxis: Clinical ConsiderationsHeadache: The Journal of Head and Face Pain, 2011
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trialCephalalgia, 2010
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trialCephalalgia, 2010
- Patterns of Diagnosis and Acute and Preventive Treatment for Migraine in the United States: Results from the American Migraine Prevalence and Prevention StudyHeadache: The Journal of Head and Face Pain, 2006
- Consensus Statement: Cardiovascular Safety Profile of Triptans (5‐HT1B/1D Agonists) in the Acute Treatment of MigraineHeadache: The Journal of Head and Face Pain, 2004
- Neuropeptides in Migraine and Cluster HeadacheCephalalgia, 1994